Why Australia’s Biggest Biotech Giant Faces Legal Scrutiny and Leadership Changes

Melbourne, Monday, 26 October 2026.
Despite rebounding shares, CSL confronts a shareholder class action over past performance disclosures alongside a massive A$2.58 billion annual net loss as a new chief executive prepares to take charge.